RARE · Ultragenyx Pharmaceutical Inc. · Webcasts, Transcripts & Audio
$16.08
-0.19 (-1.17%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.64B
Shares
101.92M
Volume · Nov 13
1.68M
Avg daily vol (3M)
4.49M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ultragenyx Pharmaceutical Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Ultragenyx Pharmaceutical Inc. (RARE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
Positive tone
Path to profitability and cost reduction
Two gene therapy launches
Citruzumab for osteogenesis imperfecta
Revenue
$173.00M
▲ 8.1% YoY Diluted EPS
$-1.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-17
Ultragenyx Pharmaceutical Inc. (RARE) September 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-19
Ultragenyx Pharmaceutical Inc. (RARE) August 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call
Positive tone
Angelman syndrome Phase III (GTX102) endpoints and design
DTX401 regulatory progress
UX143 (citruzumab) for osteogenesis imperfecta
Revenue
$214.00M
▲ 28.1% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Ultragenyx Pharmaceutical Inc. (RARE) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Ultragenyx Pharmaceutical Inc. (RARE) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call Transcript
Confident tone
GTX-102 in Angelman syndrome Phase 3 program
Global commercial expansion
Long-term GTX-102 durability and safety
Revenue
$136.00M
▼ 2.2% YoY Diluted EPS
$-1.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-10
Ultragenyx Pharmaceutical Inc. (RARE) March 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-12
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
Positive tone
UX-111 MPS-3A program and FDA resubmission
Regulatory environment / FDA biomarker scrutiny
2026 financial guidance
Revenue
$207.00M*
▲ 25.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call Transcript
Confident tone
Crysvita commercial performance and royalty financing
DTX401 in GSDIa clinical results
Other commercial products (Dojolvi, Evkeeza, Mepsevii)
Revenue
$160.00M
▲ 14.7% YoY Diluted EPS
$-1.81
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript
Confident tone
Setrusumab (UX143) Phase III
Commercial Revenue Growth
Crysvita Commercial Performance
Revenue
$167.00M
▲ 13.6% YoY Diluted EPS
$-1.17
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call
Confident tone
Gene therapy franchise (Sanfilippo and GSD1A) launches
Path to profitability in 2027 and cash management
Citruzumab regulatory path forward
Revenue
$139.00M
▲ 27.7% YoY Diluted EPS
$-1.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Confident tone
UX143 / setrusumab osteogenesis imperfecta (OI) Phase 3
GSDIa gene therapy BLA filing
Revenue and commercial growth
Revenue
$164.65M*
▲ 29.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
Confident tone
Setrusumab / UX-143 for osteogenesis imperfecta (OI)
International expansion (LatAm, EMEA, Japan)
DTX401 for GSDIa gene therapy
Revenue
$139.49M
▲ 42.3% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
Confident tone
Late-stage clinical pipeline readouts
Setrusumab / Orbit Phase 3 trial
Crysvita commercial momentum
Revenue
$147.03M
▲ 35.7% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2024 Earnings Call Transcript
Confident tone
GTX-102 Angelman Syndrome
Setrusumab Osteogenesis Imperfecta (Orbit/Cosmic)
Regulatory Engagement / FDA Endpoints
Revenue
$108.83M
▲ 8.3% YoY Diluted EPS
$-2.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2023 Earnings Call Transcript
Confident tone
Crysvita commercial performance
GTX-102 Angelman syndrome
Dojolvi (LC-FAOD) commercial
Revenue
$127.14M*
▲ 23% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-16
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2023 Earnings Call Transcript
Revenue
$98.05M
▲ 8.1% YoY Diluted EPS
$-2.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2023 Earnings Call Transcript
Revenue
$108.31M
▲ 21.2% YoY Diluted EPS
$-2.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2023 Earnings Call Transcript
Revenue
$100.50M
▲ 25.7% YoY Diluted EPS
$-2.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-06
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2022 Earnings Call Transcript
Revenue
$103.35M*
▲ 23.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2022 Earnings Call Transcript
Revenue
$90.70M
▲ 11.1% YoY Diluted EPS
$-3.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2022 Earnings Call Transcript
Revenue
$89.34M
▲ 2.7% YoY Diluted EPS
$-2.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2022 Earnings Call Transcript
Revenue
$79.94M
▼ 19.6% YoY Diluted EPS
$-2.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2021 Earnings Call Transcript
Revenue
$83.39M*
▼ 8.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2021 Earnings Call Transcript
Revenue
$81.65M
▲ 0.2% YoY Diluted EPS
$-1.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-02
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2021 Earnings Call Transcript
Revenue
$86.97M
▲ 40.9% YoY Diluted EPS
$-1.81
▼ 541.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2021 Earnings Call Transcript
Revenue
$99.39M
▲ 173.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2020 Earnings Call Transcript
Revenue
$91.54M
▲ 157.2% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2020 Earnings Call Transcript
Revenue
$81.47M
▲ 215.8% YoY Diluted EPS
$-1.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2020 Earnings Call Transcript
Revenue
$61.71M
▲ 155.5% YoY Diluted EPS
$0.41
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2020 Earnings Call Transcript
Revenue
$36.31M
▲ 99.8% YoY Diluted EPS
$-2.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2019 Earnings Call
Revenue
$35.59M
▲ 118.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–33 of 33 webcasts
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
197 filings
177 filers
Visit website
Investor relations